A Case of Gastric Cancer Treated with Resection and Adjuvant Chemotherapy in Japan after FOLFOX Neoadjuvant Chemotherapy in USA

Hidetaka A Ono, Masato Yamamoto, Emil Lou, Yukio Tsuura, Hirokazu Suwa, Yuta Minami, Kazunori Nojiri, Masatoshi Mogaki, Hidenobu Masui, Kaoru Nagahori

Research output: Contribution to journalArticlepeer-review

Abstract

A 73-year-old man, living in the United States since 1985, visited the University of Minnesota Medical Center with a complaint of upper abdominal pain in December 2019. Gastroendoscopy revealed a depressed lesion in the U area of the stomach, and the biopsy results indicated a diagnosis of por/sig. On further examination, the condition was diagnosed as gastric cancer of cStage Ⅱ/Ⅲ. A gastrectomy procedure was planned after treatment with neoadjuvant chemotherapy(NAC). After 1 course of mFOLFOX6, the patient consulted a Japanese gastroenterologist at the University of Minnesota and decided to undergo treatment in Japan. He travelled to Japan in February and visited our hospital. In March, he underwent total gastrectomy plus D2 dissection plus Roux-en-Y reconstruction. The final diagnosis was gastric cancer, U, Less, ypType 2, ypT3(ss), ypN1, sM0, yfStage ⅡB, and the therapeutic effect was Grade 2. DS therapy was started as adjuvant chemotherapy in April. After 8 courses, he returned to the United States. After moving to the United States, he personally imported S-1 and continued adjuvant chemotherapy at the University of Minnesota Hospital. The guidelines in Japan do not recommend NAC. Given that Grade 2 therapeutic effect was obtained even with 1 course of the treatment, FOLFOX therapy could be effective as preoperative chemotherapy for advanced gastric cancer cases.

Original languageEnglish (US)
Pages (from-to)1904-1906
Number of pages3
JournalGan to kagaku ryoho. Cancer & chemotherapy
Volume48
Issue number13
StatePublished - Dec 1 2021

Fingerprint

Dive into the research topics of 'A Case of Gastric Cancer Treated with Resection and Adjuvant Chemotherapy in Japan after FOLFOX Neoadjuvant Chemotherapy in USA'. Together they form a unique fingerprint.

Cite this